Company profile
JANUX THERAPEUTICS, INC.
NASDAQ:JANXBiotechnology: Pharmaceutical Preparations
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07813637 | phase1 | recruiting | 2026-09-10 | 2029-07-01 | Janux Therapeutics | Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC |
| NCT05519449 | phase1 | recruiting | 2022-09-15 | 2027-07-01 | Janux Therapeutics | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) |
| NCT05783622 | phase1 | active_not_recruiting | 2023-04-19 | 2026-07-31 | Janux Therapeutics | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies |
| NCT07291323 | — | recruiting | 2026-02-16 | 2026-10-01 | Janux Therapeutics | Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. |
| NCT07545811 | phase1 | recruiting | 2026-04-15 | 2028-05-01 | Janux Therapeutics | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer |
FDA applications (0)
No records yet.